Capricor Therapeutics, Inc.
As of Oct 22, 2026, Capricor Therapeutics is in Stage 4, the downtrend phase, now in week 12 (since Jul 31, 2026). It closed at $6.13, 82.7% below its 52-week high and below its 200-day average, which is falling.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CAPR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CAPR among Biotechnology198th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …198 | CAPR | Stage 4 · wk 12 | 51 | −29.3% |
Capricor Therapeutics: quick answers
What stage is Capricor Therapeutics in?
As of Oct 22, 2026, Capricor Therapeutics (CAPR) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 31, 2026 and is in week 12. What the four stages mean
Is Capricor Therapeutics in an uptrend?
No. Capricor Therapeutics is in a Stage 4 downtrend. It trades 71.1% below its 200-day average, which is falling.
How far is Capricor Therapeutics from its 52-week high?
Capricor Therapeutics closed at $6.13 on Oct 22, 2026, 82.7% below its 52-week high of $35.34. Its 52-week low is $3.85.
How has Capricor Therapeutics performed over the past year?
As of Oct 22, 2026, Capricor Therapeutics is down 3.8% over the past year and down 78.3% so far in 2026.
Which sector and industry is Capricor Therapeutics in?
Capricor Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.